SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Attached01-10-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 28, 2022 for Shanghvi Finance Pvt Ltd30-09-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201529-09-2022
Sun Pharma extends rally, surges 7% in two days; now trades at 5-month high
Sun Pharma could see structural growth and be relatively insulated from the adverse price erosion scenario in the US, according to analysts.29-09-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update On Acquisition Of Uractiv Portfolio
Further to the Press Release submitted vide our letter dated May 27, 2022, we wish to inform that the acquisition of UractivTM Portfolio from Fiterman Pharma in Romania closed on September 27, 2022.28-09-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201523-09-2022
Adani more than doubles wealth, Poonawallas at number 3
Sun Pharma's Dilip Shanghvi and Uday Kotak re-entered the list this year, replacing Kumar Mangalam Birla of Aditya Birla Group and Jay Chaudhary of Zscaler, according to the study based on estimates till August 30, 2022.22-09-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Axis Trustee Services Ltd21-09-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
This is to inform you that in compliance with the Company's Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons of the Company (along with his/her immediate relatives or any person with whom he/she shares a material financial relationship), shall be with effect from Saturday, October 1, 2022 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022. The date of the Board Meeting of the Company for declaration of the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022 will be intimated in due course.21-09-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201519-09-2022